Case Report
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 26, 2021; 9(36): 11419-11424
Published online Dec 26, 2021. doi: 10.12998/wjcc.v9.i36.11419
Dramatic response to immunotherapy in an epidermal growth factor receptor-mutant non-small cell lung cancer: A case report
Ding Li, Cheng Cheng, Wen-Ping Song, Pei-Zan Ni, Wen-Zhou Zhang, Xuan Wu
Ding Li, Wen-Ping Song, Wen-Zhou Zhang, Department of Pharmacy, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China
Ding Li, Wen-Ping Song, Wen-Zhou Zhang, Henan Engineering Research Center for Tumor Precision Medicine and Comprehensive Evaluation, Zhengzhou 450008, Henan Province, China
Cheng Cheng, Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China
Pei-Zan Ni, Department of Radiotherapy, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China
Xuan Wu, Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China
Author contributions: Li D and Cheng C gave medical assistance to the study population and collected the data; Song WP, Wu X and Ni PZ analyzed the data; Li D wrote the draft of the manuscript; Zhang WZ and Wu X reviewed all versions of the manuscript and helped to shape it up; all authors contributed to the article and approved the submitted version.
Supported by Henan Provincial Science and Technology Research Project, No. 202102310157; Medical Science and Technology Research Plan (Joint Construction) Project of Henan Province, No. LHGJ20190676.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xuan Wu, MD, Doctor, Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, No. 127 Dongming Road, Zhengzhou 450008, Henan Province, China. 843240113@qq.com
Received: July 4, 2021
Peer-review started: July 4, 2021
First decision: September 28, 2021
Revised: September 29, 2021
Accepted: November 18, 2021
Article in press: November 18, 2021
Published online: December 26, 2021
Processing time: 172 Days and 5.2 Hours
Core Tip

Core Tip: In this paper, we report a patient with metastatic epidermal growth factor receptor-mutant non-small cell lung cancer showed dramatic response to immunotherapy after pemetrexed plus carboplatin and achieved a durable disease control over 10 mo. We aimed to analyze the potential reasons why the patient can benefit from immunotherapy and explore the strategy that should be adopted in the future.